Glonoinum 30C,
does it really help with Rapid relief of menopausal hot flashes with accompanying headache?
research showsGlonoinum 30C is rated F for rapid relief of menopausal hot flashes and headache. A 30C preparation repeats a 100-fold dilution 30 times, producing an approximately 10^-60 dilution far beyond the Avogadro limit, with no realistic likelihood that a molecule of the starting material remains. The official DailyMed label lists sudden hot flash and headache, but this does not mean that FDA evaluated or approved efficacy, and no direct randomized trial of this exact single 30C product was found. Repeated failure of high-quality homeopathy evidence to establish specific efficacy, together with consistency with prior Coffea and Calms-class verdicts, yields F with 8 points.
ads claimA symptom statement on the label and the designation 30C can be presented as precise efficacy validation, but they reflect homeopathic labeling rather than a molecular dose or FDA efficacy approval. Rapid relief is especially unsupported because no time-resolved placebo-controlled evidence for this product was found.
Useful facts when choosing a product
- Glonoinum 30C denotes thirty successive 100-fold homeopathic dilutions, corresponding mathematically to an approximate final dilution of 10^-60.
- Publication of a label on DailyMed does not mean that the product passed FDA review for safety and efficacy, and FDA states that no homeopathic product is FDA approved.
- Direct toxicity from an ultra-dilute tablet is likely low, but manufacturing error, contamination, and delay of effective menopause or headache treatment remain concerns.
- A new sudden severe headache, neurological symptoms, chest pain, or abnormal bleeding should not be assumed to be menopause and warrants urgent medical assessment.
What the research actually shows
The Boiron Glonoinum 30C label on DailyMed lists sudden hot flash and headache, but the product is not FDA approved. Shang and colleagues compared 110 placebo-controlled homeopathy trials with 110 conventional-medicine trials and found no convincing specific effect when attention was restricted to larger, higher-quality homeopathy trials. NCCIH summarizes the 2015 Australian National Health and Medical Research Council assessment as finding no reliable evidence that homeopathy is effective for any condition. A 108-person BRN-01 trial used a five-ingredient product containing Glonoinum 4CH and is not direct evidence for the single 30C product.
Why this is classified as F (8)
The exact single product lacks a direct clinical trial, 30C greatly exceeds the Avogadro limit, and larger higher-quality homeopathy evidence and public assessments do not support specific efficacy. Repeated-refutation and corpus-consistency rules with prior Coffea and Calms-class verdicts yield F with 8 points. Low direct toxicity and lack of efficacy are separate questions.
Counterpoint. Hot flashes or headaches may improve through natural fluctuation, expectation, or supportive consultation, but that does not demonstrate a specific effect of Glonoinum 30C. Clinicians can assess headache causes and the suitability of evidence-based hormonal or nonhormonal options.
Rejudgment record. New verdict — Assigned F based on the absence of a direct Glonoinum 30C trial, dilution far beyond the Avogadro limit, repeated refutation in larger higher-quality homeopathy evidence and public assessments, and corpus consistency with prior Coffea and Calms-class verdicts
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Rapid relief of menopausal hot flashes with accompanying headache | F | No direct trial of the same single 30C product exists, and the ultra-dilute homeopathy class has been repeatedly refuted in higher-quality evidence. |
| Presence of starting-material molecules at 30C | ? | A 10^-60 dilution far exceeds the Avogadro limit and is ordinarily calculated to contain no starting molecules; this is not a clinical efficacy endpoint. |
| Rapid onset of relief | ? | No time-resolved placebo-controlled clinical data for the same product are available to assess onset speed. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Shang A et al. 2005 | Comparative meta-analysis of placebo-controlled homeopathy and conventional-medicine trials | 110 | Swiss federal social-insurance evaluation program and academic research | Specific effects versus placebo according to trial size and quality | When restricted to larger, higher-quality homeopathy trials, the result was compatible with placebo effects. | Class-level refutation; not a direct Glonoinum trial |
| NCCIH homeopathy evidence assessment | Public-agency evidence summary citing the comprehensive NHMRC assessment | U.S. NIH NCCIH and the Australian Government NHMRC | Existence of reliable efficacy evidence by health condition | It summarizes that no reliable evidence shows homeopathy effective for any health condition. | Official class-level assessment; not a direct Glonoinum trial | |
| Colau JC et al. 2012; BRN-01 | Randomized double-blind placebo-controlled multi-ingredient homeopathy trial | 108 | Product trial associated with Laboratoires Boiron | Twelve-week hot-flash score | The five-ingredient BRN-01 product had a positive signal, but Glonoinum was 4CH and the effect of single-ingredient 30C could not be isolated. | Indirect combination product with no isolated attribution |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Glonoinum 30C x rapid relief of menopausal hot flashes and headache — Evidence Grade F·8. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/glonoinum-30c-menopausal-hot-flash-headache-relief/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.